Glassbeam Awarded FedRAMP Authorization for its SAAS analytics solution for connected medical systems by the U.S. Department of Veterans Affairs.

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

This designation enables Glassbeam to support federal government agency customers increase uptime for all MRI and CT scanners and avoid costly service delays.

SANTA CLARA, Calif., June 13, 2025 /PRNewswire/ — Glassbeam, Inc., a pioneer in data and predictive analytics for connected medical machines, today announced it has received FedRAMP authorization. Delivered as a service, Clinsights Service Analytics enables federal agencies, state and local governments, and providers of critical infrastructure to improve equipment availability and service productivity.

The Federal Risk and Authorization Management Program (FedRAMP) is a federal government-wide program that provides a standardized approach to security assessment, authorization and continuous monitoring for cloud products and services. FedRAMP authorization follows a successful security audit via an accredited third-party assessor.

“Glassbeam considers it a privilege to support the VA in its vital mission to serve Veterans. Achieving FedRAMP authorization for the VA demonstrates our unwavering commitment to the secure and careful handling of critical medical data. We are eager to continue our collaboration, enhancing the healthcare experience for those who have served.,” according to Rich Jones, CEO of Glassbeam. Clinsights Service Analytics provides the only multi-vendor SaaS offering for proactive alerts in the federal marketplace, allowing federal organizations improve machine uptime, service engineer productivity and patient care by transforming maintenance services from break-fix to proactive-predictive through a highly scalable platform.

Glassbeam recently partnered with the VHA Medical Device Networking and Cybersecurity Division and has supported the U.S. Department of Veterans Affairs with a deployment of Glassbeam Service Analytics within VISN 2. 

Unexpected equipment failures, lead to unplanned downtime which disrupts patient schedules, additional costs, and reduced access for imaging departments. With the completed authorization, Glassbeam is now listed on the FedRAMP Marketplace and increasing our work with the VA to deliver improved diagnosis and issue resolution.  “We are excited to bring forward the technology to enable the monitoring and alerts for our valued customers, the VA clinicians.” stated Garth Donaldson, Vice President of Sales, Glassbeam.

Glassbeam uses artificial intelligence, predictive analytics, and machine learning to monitor medical devices, including MRI, CT scanners and other imaging equipment, in real-time to anticipate needed repairs and maximize uptime. Its ease of deployment and remote access option ensures operational efficiency while helping patients receive much-needed care, avoiding unnecessary delays.

For more information, visit Glassbeam.com.

About Glassbeam
Glassbeam is a pioneer in predictive analytics for medical devices. Our solutions enable improved uptime, utilization, and productivity by providing actionable insights.  Glassbeam’s cloud-based platform incorporates proprietary analytics and workflow to achieve tangible outcomes for organizations such as Canon Medical Systems USA, MultiCare Health System, Stanford, Brown’s Medical Imaging, and Agiliti Health. For more information, visit www.glassbeam.com.

Clinsights™ is a trademark of Glassbeam.

Press Contact
Dave Ysseldyke
Dave.ysseldyke@glassbeam.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/glassbeam-awarded-fedramp-authorization-for-its-saas-analytics-solution-for-connected-medical-systems-by-the-us-department-of-veterans-affairs-302480777.html

SOURCE Glassbeam, Inc.

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

15 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

15 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

15 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

15 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

15 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

15 hours ago